MedPath

A Telehealth-delivered Physical Therapy Program for Postmenopausal Women with Urinary Incontinence

Not Applicable
Completed
Conditions
Urinary Incontinence
Interventions
Behavioral: Pelvic floor muscle training
Registration Number
NCT05970796
Lead Sponsor
National Taiwan University
Brief Summary

Postmenopausal women frequently report physical (hot flushes, night sweat, insomnia, vaginal dryness, sexual dysfunction, urinary incontinence, reduced fitness level, osteoporotic symptoms, sarcopenia, decreased fat free mass, etc.) and psychological (depression, anxiety, cognitive decline, etc.) symptoms. Among these symptoms, urinary incontinence is one of the most common manifestations of pelvic floor dysfunction and may significantly impact on women's quality of life. Urinary incontinence is highly prevalent (30%) in postmenopausal women and is primarily attributed to the decreased level of estrogen. Other potential risk factors for urinary incontinence after menopause include age, parity, genetic factors, pregnancy, overweight/obesity, low physical activity levels, diabetes, urinary tract infection, etc. International guidelines recommend lifestyle and behavioral change, pelvic floor muscle training and bladder training as first-line treatments for urinary incontinence in postmenopausal women. During the COVID-19 pandemic, access to and utilization of healthcare services is reduced. As travel distance has been reported as one of the strong barriers to healthcare among patients with incontinence, research has been conducted to investigate the applications and effects of telehealth. While telehealth rehabilitation may improve urinary incontinence symptoms, the field is still emerging and more studies are needed to elucidate how physical therapists can perform telehealth pelvic floor muscle training for urinary incontinence.

The objectives of this three-year study are:

1. to investigate the feasibility of a telehealth-delivered physical therapy program for postmenopausal women with urinary incontinence

2. to explore the effects of a telehealth-delivered physical therapy program on urinary incontinence symptoms, pelvic floor muscle function and quality of life in postmenopausal women with urinary incontinence

3. to compare the effectiveness of telehealth physical therapy program with face-to-face physical therapy in this population

4. to compare body composition, physical activity levels, functional capacity, grip strength, urinary incontinence symptoms, and pelvic floor muscles function in women at early versus late stage of post-menopause

5. to evaluate the relationships between duration after menopause and body composition, physical activity levels, functional capacity, grip strength, urinary incontinence symptoms, and pelvic floor muscles function

Detailed Description

This is a non-inferiority randomized controlled trial with a nested cross-sectional study and a nested qualitative interview study. Sixty community-dwelling postmenopausal women with urinary incontinence, aged \>40 years, will be recruited and randomly allocated to two groups, telehealth group or face-to-face group. All groups will receive a 12-week pelvic floor muscle training. The face-to-face group will be supervised by a female physical therapist who will provide pelvic floor muscle training twice a week. The training will be adjusted according to the performance of the participant. The telehealth group will receive eight sessions of individualized pelvic floor muscle training provided by a physical therapist via telehealth in addition to a weekly telephone coaching. The baseline, post-intervention, and 3-month follow-up assessments will include feasibility outcomes, measurements of anthropometry, body composition (body composition monitor), hand grip strength (dynamometer), functional exercise capacity (six minute walk test), and pelvic floor muscle function (vaginal manometry, transperineal ultrasound and digital palpation) and two questionnaires about symptom severity of urinary incontinence and physical activity levels. This study will provide evidence of effectiveness of different delivery modes of physical therapy program for postmenopausal women with urinary incontinence and health-care professionals working with this population in clinical practice.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
22
Inclusion Criteria
  1. women aged over 40 years
  2. postmenopausal women: amenorrhea for longer than 12 months
  3. having symptomatic UI (defined as having the Questionnaire for Urinary Incontinence Diagnosis score > 0 point)
  4. being able to answer the questionnaire correctly (no language barrier or cognitive problems)
  5. having no other physical or psychological problem that would interfere participation in the study
  6. having access to a mobile video conference device with internet access
Exclusion Criteria
  1. women aged over 85 years old
  2. receiving hormone therapy
  3. having neurological conditions, malignancy for pelvic organ, overflow incontinence or voiding dysfunction
  4. had received radical surgery for pelvis, sling or prolapse surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Face-to-face groupPelvic floor muscle trainingThe face-to-face group will be supervised by a female physical therapist who will provide pelvic floor muscle training twice a week for 12 weeks.
Telehealth groupPelvic floor muscle trainingThe telehealth group will receive eight sessions of individualized pelvic floor muscle training provided by a physical therapist via telehealth in 12 weeks.
Primary Outcome Measures
NameTimeMethod
Satisfaction scaleabsolute values at 12 weeks

Satisfaction will be was assessed using a five-point Likert-scale ranging from '1 = very dissatisfied' to '5 = very satisfied'.

Number of intervention sessions attendedabsolute values at 12 weeks

Attendance rate: number of sessions attended will be divided by the total number of expected sessions within each treatment arm

Number of participants consented to participateabsolute values at baseline

Consent rate: number of participants enrolled will be divided by number of eligible patients approached

Number of completed training sessions in relation to the scheduled sessionsabsolute values at 12 weeks

Adherence rate: the total number of exercise sessions completed as a proportion of that prescribed each week from baseline to 12 week.

Number of participants with intervention-related adverse events as assessed by CTCAE v4.0absolute values at 12 weeks

Adverse events: the number of adverse or serious adverse events throughout the 12-week intervention period. Participants will be asked about any symptoms (such as pain, bleeding or itching) at each training session.

Number of participants who remain in the study 3 months after baseline assessmentabsolute values at 3 months

Retention rate: number of participants who remain in the study at 3-month follow-up as a proportion of the total number of participants recruited at the baseline assessment

Number of participants who withdrew from the trialabsolute values at 12 weeks and 3 months

Withdrawal rate: number of participants who withdraw from the trial after consenting divided by the number of participants who initially consent to the trial

Acceptability scaleabsolute values at 12 weeks

Acceptability will be was assessed using a five-point Likert-scale ranging from '1 = very dissatisfied' to '5 = very satisfied'.

Secondary Outcome Measures
NameTimeMethod
Weightabsolute values at 12 weeks and 3 months

Weight in kilograms will be measured using a Full Body Sensor Body Composition Monitor.

Body mass indexabsolute values at 12 weeks and 3 months

Weight and height will be combined to report body mass index in kg/m\^2

Anorectal angleabsolute values at 12 weeks and 3 months

Anorectal angle will be measured using a transperineal ultrasound. The anorectal angle between the anal canal longitudinal axis and the posterior rectal line will be measured in degrees at rest and during maximal voluntary contraction.

Physical activity levelsabsolute values at 12 weeks and 3 months

The International Physical Activity Questionnaire - Short Form will be used to measure total physical activity levels in MET minutes a week with a higher score corresponding to a higher physical activity level.

Heightabsolute values at 12 weeks and 3 months

Height in meters will be measured using a measuring tape.

Severity of urinary incontinenceabsolute values at 12 weeks and 3 months

The severity of urinary incontinence will be measured using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form. The total score ranges from 0-21 with a higher score indicating greater severity of symptoms.

Handgrip strengthabsolute values at 12 weeks and 3 months

The grip strength of dominant hand will be measured in kilograms using a Jamar Plus+ Dynamometer.

Pelvic floor muscle strengthabsolute values at 12 weeks and 3 months

Pelvic floor muscle strength will be measured using digital palpation. The results will be recorded using the modified Oxford Grading scale, which quantifies pelvic floor muscle strength as: 0, no contraction; 1, flicker; 2, weak; 3, moderate; 4, good; and 5, strong.

Bladder neck descentabsolute values at 12 weeks and 3 months

Bladder neck descent will be measured in centimeters using a transperineal ultrasound at rest and during maximal voluntary contraction.

Body fat percentageabsolute values at 12 weeks and 3 months

Body fat percentage will be measured using a Full Body Sensor Body Composition Monitor. Body fat percentage will be classified as 5.0 to 19.9% (low), 20.0 to 29.9% (normal), 30.0 to 34.9% (high), and 35.0% and above (very high).

Skeletal muscle percentageabsolute values at 12 weeks and 3 months

Skeletal muscle percentage will be measured using a Full Body Sensor Body Composition Monitor. Skeletal muscle percentage will be classified as 5.0 to 25.8% (low), 25.9 to 37.9% (normal), 28.0 to 29.0% (high), and 29.1 to 60.0% (very high).

Functional exercise capacityabsolute values at 12 weeks and 3 months

Functional exercise capacity will be assessed using six-minute walk test. The distance covered over a time of 6 minutes will be recorded in meters.

Visceral fat levelabsolute values at 12 weeks and 3 months

Visceral fat level will be measured using a Full Body Sensor Body Composition Monitor. Visceral fat level will be classified as 1 to 9 (normal), 10 to 14 (high), and 15 to 30 (very high).

Anteroposterior diameter of the urogenital levator hiatusabsolute values at 12 weeks and 3 months

Anteroposterior diameter of the urogenital levator hiatus will be measured in centimeters using a transperineal ultrasound at rest and during maximal voluntary contraction.

Trial Locations

Locations (1)

National Taiwan University

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath